The survey results showed that in the real‐life setting the response rate of the 3/7 + midostaurin regimen in newly diagnosed FLT3‐mutated AML and of gilteritinib in the relapsed/refractory AML were comparable to that reported in the registrative clinical trials. Here, FLT3 is linked to acute myeloid leukemia.